Business Practice

What does the legalization of medical cannabis mean for conventional pharmaceuticals?

PhRMA and the ABPI showcase the industry’s good side and the science behind the logo.

Marathon Pharmaceuticals’ pricing of Emflaza for Duchenne muscular dystrophy causes controversy

It’s not easy finding your way “from a garage to a palace...”

Sitting Down With Dominic Carolan, CEO of NIBRT.

Pharma needs new business model designs and analytics to help measure value.

Men continue to dominate upper management positions, but could flexible working change this?

What was hot in 2016? And what should pharma's priorities lie in 2017?

How inspiration from the airline industry could help improve the biosimilars industry.

A patent surprise, authorization denied, and EpiPen’s monopoly compromised...